Literature DB >> 16269556

Ethical considerations in the application of preconditioning to solid organ transplantation.

S J McNally1, E M Harrison, S J Wigmore.   

Abstract

The shortage of organs for transplantation has led researchers to look for new techniques to expand the donor pool. Preconditioning strategies have the potential to protect organs from transplant associated injury or may improve the function of substandard organs so that they become suitable for transplantation. Translating this type of technology to the clinical setting raises ethical issues, particularly relating to the deceased donor. It is important that society has the opportunity to discuss the issues raised by implementation of preconditioning strategies before they are implemented rather than as a reaction to them.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Year:  2005        PMID: 16269556      PMCID: PMC1734053          DOI: 10.1136/jme.2004.011486

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  17 in total

1.  Attenuation of hepatic microcirculatory failure during in situ xenogeneic rat liver perfusion by heat shock preconditioning.

Authors:  H Terajima; A Thiaener; C Hammer; K Messmer; Y Yamamoto; Y Yamaoka
Journal:  Transplant Proc       Date:  2000-08       Impact factor: 1.066

2.  Aggressive pharmacologic donor management results in more transplanted organs.

Authors:  John D Rosendale; H Myron Kauffman; Maureen A McBride; Franki L Chabalewski; Jonathan G Zaroff; Edward R Garrity; Francis L Delmonico; Bruce R Rosengard
Journal:  Transplantation       Date:  2003-02-27       Impact factor: 4.939

Review 3.  Mechanisms of ischemic preconditioning and its application in transplantation.

Authors:  Maciej Kosieradzki
Journal:  Ann Transplant       Date:  2002       Impact factor: 1.530

Review 4.  Trends in organ preservation.

Authors:  Andrew James McLaren; Peter John Friend
Journal:  Transpl Int       Date:  2003-10-07       Impact factor: 3.782

5.  Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney.

Authors:  C W Yang; H J Ahn; H J Han; W Y Kim; C Li; M J Shin; S K Kim; J H Park; Y S Kim; I S Moon; B K Bang
Journal:  Transplantation       Date:  2001-12-15       Impact factor: 4.939

6.  Hyperthermia-induced HSP expression correlates with improved rat renal isograft viability and survival in kidneys harvested from non-heart-beating donors.

Authors:  C A Redaelli; M Wagner; C Kulli; Y H Tian; D Kubulus; L Mazzucchelli; A C Wagner; M K Schilling
Journal:  Transpl Int       Date:  2001-12       Impact factor: 3.782

Review 7.  Kidney transplantation from non heart-beating donors.

Authors:  N R Brook; M L Nicholson
Journal:  Surgeon       Date:  2003-12       Impact factor: 2.392

Review 8.  Protection of the liver by ischemic preconditioning: a review of mechanisms and clinical applications.

Authors:  Rahul S Koti; Alexander M Seifalian; Brian R Davidson
Journal:  Dig Surg       Date:  2003-07-02       Impact factor: 2.588

9.  Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection.

Authors:  Christine Chauveau; Delphine Bouchet; Jean-Christian Roussel; Patrick Mathieu; Cécile Braudeau; Karine Renaudin; Laurent Tesson; Jean-Paul Soulillou; Suhasini Iyer; Roland Buelow; Ignacio Anegon
Journal:  Am J Transplant       Date:  2002-08       Impact factor: 8.086

10.  A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning.

Authors:  Pierre-Alain Clavien; Markus Selzner; Hannes A Rüdiger; Rolf Graf; Zakiyah Kadry; Valentin Rousson; Wolfram Jochum
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

View more
  1 in total

Review 1.  Advancing stem cell therapy from bench to bedside: lessons from drug therapies.

Authors:  Thekkeparambil Chandrabose Srijaya; Thamil Selvee Ramasamy; Noor Hayaty Abu Kasim
Journal:  J Transl Med       Date:  2014-09-04       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.